Detalhe da pesquisa
1.
Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma.
Clin Cancer Res
; 26(10): 2327-2336, 2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32034074